Form 8-K - Current report:
SEC Accession No. 0001558370-22-017765
Filing Date
2022-11-14
Accepted
2022-11-14 16:16:17
Documents
14
Period of Report
2022-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aytu-20221114x8k.htm   iXBRL 8-K 35952
2 EX-99 aytu-20221114xex99.htm EX-99 275273
3 GRAPHIC aytu-20221114xex99001.jpg GRAPHIC 4381
  Complete submission text file 0001558370-22-017765.txt   457542

Data Files

Seq Description Document Type Size
4 EX-101.SCH aytu-20221114.xsd EX-101.SCH 3131
5 EX-101.LAB aytu-20221114_lab.xml EX-101.LAB 15903
6 EX-101.PRE aytu-20221114_pre.xml EX-101.PRE 10060
8 EXTRACTED XBRL INSTANCE DOCUMENT aytu-20221114x8k_htm.xml XML 4914
Mailing Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112
Business Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

EIN.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 221385586
SIC: 2834 Pharmaceutical Preparations